Literature DB >> 12586616

High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia.

Helen McCarthy1, William G Wierda, Lynn L Barron, Candy C Cromwell, Jing Wang, Kevin R Coombes, Roberto Rangel, Kojo S J Elenitoba-Johnson, Michael J Keating, Lynne V Abruzzo.   

Abstract

In chronic lymphocytic leukemia (CLL), analysis of immunoglobulin heavy chain variable regions for somatic hypermutation identifies 2 prognostic subsets, mutated and unmutated. Investigators have postulated that unmutated and mutated CLL arises from malignant transformation of pre- and post-germinal center (GC) B cells, respectively. Alternatively, unmutated cases may arise from B cells stimulated by T-cell-independent antigens or from GC B cells with inactive somatic hypermutation. Activation-induced cytidine deaminase (AID), a protein essential for somatic hypermutation, is expressed by GC B cells in which this process occurs. We investigated AID mRNA expression in 20 CLL cases. In 8 cases we detected high expression of wild-type AID mRNA and 2 splice variants; in 12 cases and 5 normal peripheral blood B-cell samples we detected no expression using standard conditions. Of 8 CLL cases that highly expressed AID, 7 were unmutated, suggesting that this subset may arise from GC-experienced B cells with inactive somatic hypermutation, and may predict prognosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586616     DOI: 10.1182/blood-2002-09-2906

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

Review 1.  Functions and regulation of the APOBEC family of proteins.

Authors:  Harold C Smith; Ryan P Bennett; Ayse Kizilyer; William M McDougall; Kimberly M Prohaska
Journal:  Semin Cell Dev Biol       Date:  2011-10-06       Impact factor: 7.727

Review 2.  The dark side of activation-induced cytidine deaminase: relationship with leukemia and beyond.

Authors:  Kazuo Kinoshita; Taichiro Nonaka
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

3.  Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology.

Authors:  Lynne V Abruzzo; Lynn L Barron; Keith Anderson; Rachel J Newman; William G Wierda; Susan O'brien; Alessandra Ferrajoli; Madan Luthra; Sameer Talwalkar; Rajyalakshmi Luthra; Dan Jones; Michael J Keating; Kevin R Coombes
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

Review 4.  Malleable immunoglobulin genes and hematopathology - the good, the bad, and the ugly: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.

Authors:  Adam Bagg
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

5.  Biological validation of differentially expressed genes in chronic lymphocytic leukemia identified by applying multiple statistical methods to oligonucleotide microarrays.

Authors:  Lynne V Abruzzo; Jing Wang; Mini Kapoor; L Jeffrey Medeiros; Michael J Keating; W Edward Highsmith; Lynn L Barron; Candy C Cromwell; Kevin R Coombes
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

6.  HSP90 inhibitors decrease AID levels and activity in mice and in human cells.

Authors:  Damien Montamat-Sicotte; Ludivine C Litzler; Cecilia Abreu; Shiva Safavi; Astrid Zahn; Alexandre Orthwein; Markus Müschen; Pablo Oppezzo; Denise P Muñoz; Javier M Di Noia
Journal:  Eur J Immunol       Date:  2015-05-18       Impact factor: 5.532

7.  Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.

Authors:  Joan H Admirand; Ronald J Knoblock; Kevin R Coombes; Constantine Tam; Ellen J Schlette; William G Wierda; Alessandra Ferrajoli; Susan O'Brien; Michael J Keating; Rajyalakshmi Luthra; L Jeffrey Medeiros; Lynne V Abruzzo
Journal:  Mod Pathol       Date:  2010-07-23       Impact factor: 7.842

8.  IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.

Authors:  Piers E M Patten; Charles C Chu; Emilia Albesiano; Rajendra N Damle; Xiao-Jie Yan; Dorothy Kim; Lu Zhang; Amanda R Magli; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Sergio Roa; Patricia K Mongini; Thomas MacCarthy; Matthew D Scharff; Nicholas Chiorazzi
Journal:  Blood       Date:  2012-10-15       Impact factor: 22.113

9.  Ig V region restrictions in human chronic lymphocytic leukemia suggest some cases have a common origin.

Authors:  Grant R Kolar; J Donald Capra
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

10.  Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells.

Authors:  Xiaosheng Wu; Jaime R Darce; Sook Kyung Chang; Grzegorz S Nowakowski; Diane F Jelinek
Journal:  Blood       Date:  2008-08-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.